10
Participants
Start Date
July 8, 2021
Primary Completion Date
April 11, 2024
Study Completion Date
April 11, 2024
Pemigatinib
Pemigatinib tablets taken by mouth once daily as per protocol
Retifanlimab
Retifanlimab is administered over 60 minutes once every 4 weeks (Day 1 of a 28-day cycle)
Pembrolizumab
Commercially labeled products
Fondazione Irccs Istituto Nazionale Dei Tumori, Milan
Virginia Cancer Specialists, Pc, Fairfax
Oncology Specialists of Charlotte, Charlotte
Azienda Ospedaliera Universitaria Senese Policlinico Santa Maria Alle Scotte, Siena
Md Anderson Cancer Center, Houston
South Texas Accelerated Research Therapeutics, San Antonio
John Wayne Cancer Institute, Santa Monica
The Finsen Centre National Hospital, Copenhagen
Istituto Nazionale Tumori Regina Elena Irccs, Rome
Kanagawa Cancer Center, Yokohama
Lead Sponsor
Incyte Corporation
INDUSTRY